Search Results

Your search for Prudence Francis, MD, and Hope Rugo, MD matches 2 pages

Showing 1 - 2

By Prudence Francis, MD, and Hope Rugo, MD / 2014 San Antonio Breast Cancer Symposium

Prudence Francis, MD, and Hope Rugo, MD, on the Phase III SOFT Trial

Prudence Francis, MD, of Peter MacCallum Cancer Centre, and Hope Rugo, MD, of the University of California, San Francisco, discuss data from abstract S3-08, "Randomized comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in premenopausal women with hormone...

breast cancer

By Alice Goodman / January 25, 2015

Ovarian Suppression Plus Hormonal Therapy May Be Practice-Changing in Premenopausal Hormone Receptor–Positive Early-Stage Breast Cancer

Results of the large International Breast Cancer Study Group (IBCSG)-coordinated SOFT trial present a convincing argument for the addition of ovarian function suppression to adjuvant hormonal therapy to reduce the risk of tumor recurrence in younger women with hormone receptor–positive early-stage...

Dec

Today In Oncology

Search Results

Your search for Prudence Francis, MD, and Hope Rugo, MD matches 2 pages

Prudence Francis, MD, and Hope Rugo, MD, on the Phase III SOFT Trial

Ovarian Suppression Plus Hormonal Therapy May Be Practice-Changing in Premenopausal Hormone Receptor–Positive Early-Stage Breast Cancer

Study Finds Daratumumab Monotherapy Prevented or Delayed Progression From Smoldering to Active Multiple Myeloma

Study Finds Genetic Changes, Elevated Leukemia Risk in Ground Zero First Responders

MRI First Strategy May Be Safe for Prostate Cancer Detection

Addition of SBRT to Systemic Therapy May Improve Outcomes in Select Patients With Locally Advanced Hepatocellular Carcinoma

Epcoritamab Monotherapy for Pretreated Relapsed or Refractory CLL